The recent findings of a study led by the U.S. Food and Drug Administration (FDA) may cause a manufacturer preparing to defend numerous Byetta lawsuit filings to face increased litigation over another diabetes medication.

According to a notice posted on the FDA’s website, an increased risk of heart failure has been found among patients taking Onglyza, an incretin mimetic developed by Bristol-Myers Squibb and AstraZeneca. These findings were published on February 11th, 2014, just days after the British pharmaceutical giant announced its recent purchase of Bristol-Myers-Squibb’s Type 2 diabetes drugs. Another one of the company’s products has been tied to serious side effects in lawsuits alleging Byetta pancreatic cancer and pancreatitis.

The results of this federal investigation follow a study published last year in the New England Journal of Medicine. Among other things, researchers learned that individuals who took Onglyza were more likely to be hospitalized due to heart failure than those who were given a placebo. This research was funded by Bristol-Myers Squibb and AstraZeneca, and incorporated data from 16,000 patients.

In its announcement about Onglyza, the FDA reminded the public of its ongoing investigation into the safety of all incretin mimetics. This belongs to a class of diabetes medications that mimic the actions of incretin, a hormone that stimulates the production of insulin.

According to the FDA, the analysis is “part of a broader evaluation of all type 2 diabetes drug therapies and cardiovascular risk.”

Byetta Pancreatic Cancer Lawsuits Continue to Be Filed in Federal Litigation

Heart problems are not the only side effects that may result from use of incretin mimetics. According to court documents, at least 260 Byetta lawsuit claims, as well as other cases involving the diabetes drugs have been consolidated in the U.S. District Court, Southern District of California. Plaintiffs in these cases allege that manufacturers failed to warn about the serious pancreatic side effects that may stem from use of the medications, which may include pancreatitis and pancreatic cancer. Lawsuits further allege that drugs like Byetta, Januvia and Victoza were designed defectively.

In March 2013, the FDA reportedly began investigating incretin mimetics after learning from a previously unpublished study that they may cause precancerous changes in the cells of the pancreas.

File a Byetta Lawsuit Today

If you developed pancreatic cancer or pancreatitis after taking Byetta, call our Firm to learn if you are eligible to file a lawsuit against its manufacturer. Our attorneys can be reached directly at (877) 779-1414.

Published February 13, 2014 by